Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 46

1.

Enhanced Factor IX Activity following Administration of AAV5-R338L "Padua" Factor IX versus AAV5 WT Human Factor IX in NHPs.

Spronck EA, Liu YP, Lubelski J, Ehlert E, Gielen S, Montenegro-Miranda P, de Haan M, Nijmeijer B, Ferreira V, Petry H, van Deventer SJ.

Mol Ther Methods Clin Dev. 2019 Sep 26;15:221-231. doi: 10.1016/j.omtm.2019.09.005. eCollection 2019 Dec 13.

2.

Publisher Correction: Nuclear pores as versatile reference standards for quantitative superresolution microscopy.

Thevathasan JV, Kahnwald M, Cieśliński K, Hoess P, Peneti SK, Reitberger M, Heid D, Kasuba KC, Hoerner SJ, Li Y, Wu YL, Mund M, Matti U, Pereira PM, Henriques R, Nijmeijer B, Kueblbeck M, Sabinina VJ, Ellenberg J, Ries J.

Nat Methods. 2019 Dec;16(12):1332. doi: 10.1038/s41592-019-0659-5.

PMID:
31653976
3.

Photoactivation of silicon rhodamines via a light-induced protonation.

Frei MS, Hoess P, Lampe M, Nijmeijer B, Kueblbeck M, Ellenberg J, Wadepohl H, Ries J, Pitsch S, Reymond L, Johnsson K.

Nat Commun. 2019 Oct 8;10(1):4580. doi: 10.1038/s41467-019-12480-3.

4.

Nuclear pores as versatile reference standards for quantitative superresolution microscopy.

Thevathasan JV, Kahnwald M, Cieśliński K, Hoess P, Peneti SK, Reitberger M, Heid D, Kasuba KC, Hoerner SJ, Li Y, Wu YL, Mund M, Matti U, Pereira PM, Henriques R, Nijmeijer B, Kueblbeck M, Sabinina VJ, Ellenberg J, Ries J.

Nat Methods. 2019 Oct;16(10):1045-1053. doi: 10.1038/s41592-019-0574-9. Epub 2019 Sep 27. Erratum in: Nat Methods. 2019 Dec;16(12):1332.

PMID:
31562488
5.

Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men.

Nijmeijer BM, Koopsen J, Schinkel J, Prins M, Geijtenbeek TB.

J Int AIDS Soc. 2019 Aug;22 Suppl 6:e25348. doi: 10.1002/jia2.25348. Review.

6.

Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1.

Nijmeijer BM, Geijtenbeek TBH.

Front Immunol. 2019 Jul 10;10:1599. doi: 10.3389/fimmu.2019.01599. eCollection 2019. Review.

7.

First platinum(II)-based metal-organic linker technology (Lx®) for a plug-and-play development of antibody-drug conjugates (ADCs).

Merkul E, Sijbrandi NJ, Muns JA, Aydin I, Adamzek K, Houthoff HJ, Nijmeijer B, Van Dongen GAMS.

Expert Opin Drug Deliv. 2019 Aug;16(8):783-793. doi: 10.1080/17425247.2019.1645118. Epub 2019 Jul 24.

PMID:
31327255
8.

Direct Visualization of Single Nuclear Pore Complex Proteins Using Genetically-Encoded Probes for DNA-PAINT.

Schlichthaerle T, Strauss MT, Schueder F, Auer A, Nijmeijer B, Kueblbeck M, Jimenez Sabinina V, Thevathasan JV, Ries J, Ellenberg J, Jungmann R.

Angew Chem Int Ed Engl. 2019 Sep 9;58(37):13004-13008. doi: 10.1002/anie.201905685. Epub 2019 Aug 21.

9.

Therapeutic hFIX Activity Achieved after Single AAV5-hFIX Treatment in Hemophilia B Patients and NHPs with Pre-existing Anti-AAV5 NABs.

Majowicz A, Nijmeijer B, Lampen MH, Spronck L, de Haan M, Petry H, van Deventer SJ, Meyer C, Tangelder M, Ferreira V.

Mol Ther Methods Clin Dev. 2019 May 28;14:27-36. doi: 10.1016/j.omtm.2019.05.009. eCollection 2019 Sep 13.

10.

HIV-1 exposure and immune activation enhance sexual transmission of Hepatitis C virus by primary Langerhans cells.

Nijmeijer BM, Sarrami-Forooshani R, Steba GS, Schreurs RR, Koekkoek SM, Molenkamp R, Schinkel J, Reiss P, Siegenbeek van Heukelom ML, van der Valk M, Ribeiro CM, Geijtenbeek TB.

J Int AIDS Soc. 2019 Mar;22(3):e25268. doi: 10.1002/jia2.25268.

11.

Experimental and computational framework for a dynamic protein atlas of human cell division.

Cai Y, Hossain MJ, Hériché JK, Politi AZ, Walther N, Koch B, Wachsmuth M, Nijmeijer B, Kueblbeck M, Martinic-Kavur M, Ladurner R, Alexander S, Peters JM, Ellenberg J.

Nature. 2018 Sep;561(7723):411-415. doi: 10.1038/s41586-018-0518-z. Epub 2018 Sep 10.

12.

Optimization of viral protein ratios for production of rAAV serotype 5 in the baculovirus system.

Bosma B, du Plessis F, Ehlert E, Nijmeijer B, de Haan M, Petry H, Lubelski J.

Gene Ther. 2018 Sep;25(6):415-424. doi: 10.1038/s41434-018-0034-7. Epub 2018 Aug 1.

PMID:
30069004
13.

Dual-spindle formation in zygotes keeps parental genomes apart in early mammalian embryos.

Reichmann J, Nijmeijer B, Hossain MJ, Eguren M, Schneider I, Politi AZ, Roberti MJ, Hufnagel L, Hiiragi T, Ellenberg J.

Science. 2018 Jul 13;361(6398):189-193. doi: 10.1126/science.aar7462.

PMID:
30002254
14.

Generation and validation of homozygous fluorescent knock-in cells using CRISPR-Cas9 genome editing.

Koch B, Nijmeijer B, Kueblbeck M, Cai Y, Walther N, Ellenberg J.

Nat Protoc. 2018 Jun;13(6):1465-1487. doi: 10.1038/nprot.2018.042. Epub 2018 May 24.

15.

C-Type Lectin Receptors in Antiviral Immunity and Viral Escape.

Bermejo-Jambrina M, Eder J, Helgers LC, Hertoghs N, Nijmeijer BM, Stunnenberg M, Geijtenbeek TBH.

Front Immunol. 2018 Mar 26;9:590. doi: 10.3389/fimmu.2018.00590. eCollection 2018. Review.

16.

Real-time 3D single-molecule localization using experimental point spread functions.

Li Y, Mund M, Hoess P, Deschamps J, Matti U, Nijmeijer B, Sabinina VJ, Ellenberg J, Schoen I, Ries J.

Nat Methods. 2018 May;15(5):367-369. doi: 10.1038/nmeth.4661. Epub 2018 Apr 9.

17.

Complement-dependent cytotoxicity induced by therapeutic antibodies in B-cell acute lymphoblastic leukemia is dictated by target antigen expression levels and augmented by loss of membrane-bound complement inhibitors.

Loeff FC, van Egmond HME, Nijmeijer BA, Falkenburg JHF, Halkes CJ, Jedema I.

Leuk Lymphoma. 2017 Sep;58(9):1-14. doi: 10.1080/10428194.2017.1281411. Epub 2017 Jan 31.

PMID:
28140725
18.

ARHGEF17 is an essential spindle assembly checkpoint factor that targets Mps1 to kinetochores.

Isokane M, Walter T, Mahen R, Nijmeijer B, Hériché JK, Miura K, Maffini S, Ivanov MP, Kitajima TS, Peters JM, Ellenberg J.

J Cell Biol. 2016 Mar 14;212(6):647-59. doi: 10.1083/jcb.201408089. Epub 2016 Mar 7.

19.

Identifying inhibitory compounds in lignocellulosic biomass hydrolysates using an exometabolomics approach.

Zha Y, Westerhuis JA, Muilwijk B, Overkamp KM, Nijmeijer BM, Coulier L, Smilde AK, Punt PJ.

BMC Biotechnol. 2014 Mar 21;14:22. doi: 10.1186/1472-6750-14-22.

20.

Differential effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway in acute lymphoblastic leukemia.

Badura S, Tesanovic T, Pfeifer H, Wystub S, Nijmeijer BA, Liebermann M, Falkenburg JH, Ruthardt M, Ottmann OG.

PLoS One. 2013 Nov 14;8(11):e80070. doi: 10.1371/journal.pone.0080070. eCollection 2013.

21.

Structural basis of histone H2A-H2B recognition by the essential chaperone FACT.

Hondele M, Stuwe T, Hassler M, Halbach F, Bowman A, Zhang ET, Nijmeijer B, Kotthoff C, Rybin V, Amlacher S, Hurt E, Ladurner AG.

Nature. 2013 Jul 4;499(7456):111-4. doi: 10.1038/nature12242. Epub 2013 May 22.

PMID:
23698368
22.

Donor T cells administered over HLA class II barriers mediate antitumor immunity without broad off-target toxicity in a NOD/scid mouse model of acute leukemia.

Stevanović S, Nijmeijer BA, van Schie ML, Salvatori DC, Maas S, Griffioen M, Falkenburg JH.

Biol Blood Marrow Transplant. 2013 Jun;19(6):867-75. doi: 10.1016/j.bbmt.2013.03.003. Epub 2013 Mar 13.

23.

Recognition of mono-ADP-ribosylated ARTD10 substrates by ARTD8 macrodomains.

Forst AH, Karlberg T, Herzog N, Thorsell AG, Gross A, Feijs KL, Verheugd P, Kursula P, Nijmeijer B, Kremmer E, Kleine H, Ladurner AG, Schüler H, Lüscher B.

Structure. 2013 Mar 5;21(3):462-75. doi: 10.1016/j.str.2012.12.019.

24.

Imatinib mesylate at therapeutic doses has no impact on folliculogenesis or spermatogenesis in a leukaemic mouse model.

Schultheis B, Nijmeijer BA, Yin H, Gosden RG, Melo JV.

Leuk Res. 2012 Mar;36(3):271-4. doi: 10.1016/j.leukres.2011.09.025. Epub 2011 Oct 20.

PMID:
22018447
25.

Human allo-reactive CD4+ T cells as strong mediators of anti-tumor immunity in NOD/scid mice engrafted with human acute lymphoblastic leukemia.

Stevanović S, Griffioen M, Nijmeijer BA, van Schie ML, Stumpf AN, Rutten CE, Willemze R, Falkenburg JH.

Leukemia. 2012 Feb;26(2):312-22. doi: 10.1038/leu.2011.222. Epub 2011 Aug 23.

PMID:
21860431
26.

IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors.

Bondanza A, Hambach L, Aghai Z, Nijmeijer B, Kaneko S, Mastaglio S, Radrizzani M, Fleischhauer K, Ciceri F, Bordignon C, Bonini C, Goulmy E.

Blood. 2011 Jun 16;117(24):6469-78. doi: 10.1182/blood-2010-11-320366. Epub 2011 Apr 29.

PMID:
21531977
27.

A mechanistic rationale for combining alemtuzumab and rituximab in the treatment of ALL.

Nijmeijer BA, van Schie ML, Halkes CJ, Griffioen M, Willemze R, Falkenburg JH.

Blood. 2010 Dec 23;116(26):5930-40. doi: 10.1182/blood-2010-01-262006. Epub 2010 Sep 15.

PMID:
20844239
28.

A macrodomain-containing histone rearranges chromatin upon sensing PARP1 activation.

Timinszky G, Till S, Hassa PO, Hothorn M, Kustatscher G, Nijmeijer B, Colombelli J, Altmeyer M, Stelzer EH, Scheffzek K, Hottiger MO, Ladurner AG.

Nat Struct Mol Biol. 2009 Sep;16(9):923-9. doi: 10.1038/nsmb.1664. Epub 2009 Aug 13.

PMID:
19680243
29.

Long-term culture of primary human lymphoblastic leukemia cells in the absence of serum or hematopoietic growth factors.

Nijmeijer BA, Szuhai K, Goselink HM, van Schie ML, van der Burg M, de Jong D, Marijt EW, Ottmann OG, Willemze R, Falkenburg JH.

Exp Hematol. 2009 Mar;37(3):376-85. doi: 10.1016/j.exphem.2008.11.002. Epub 2009 Jan 9.

PMID:
19135770
30.

Establishment and cytogenetic characterization of a human acute lymphoblastic leukemia cell line (ALL-VG) with ETV6/ABL1 rearrangement.

Baeumler J, Szuhai K, Falkenburg JH, van Schie ML, Ottmann OG, Nijmeijer BA.

Cancer Genet Cytogenet. 2008 Aug;185(1):37-42. doi: 10.1016/j.cancergencyto.2008.05.001.

PMID:
18656692
31.

The pluripotency rheostat Nanog functions as a dimer.

Mullin NP, Yates A, Rowe AJ, Nijmeijer B, Colby D, Barlow PN, Walkinshaw MD, Chambers I.

Biochem J. 2008 Apr 15;411(2):227-31. doi: 10.1042/BJ20080134.

PMID:
18290762
32.

Nanog safeguards pluripotency and mediates germline development.

Chambers I, Silva J, Colby D, Nichols J, Nijmeijer B, Robertson M, Vrana J, Jones K, Grotewold L, Smith A.

Nature. 2007 Dec 20;450(7173):1230-4.

PMID:
18097409
33.

Limited antitumor-effect associated with toxicity of the experimental cytotoxic drug cyclopentenyl cytosine in NOD/scid mice with acute lymphoblastic leukemia.

Schimmel KJ, Nijmeijer BA, van Schie ML, Falkenburg JH, Guchelaar HJ.

Leuk Res. 2007 Nov;31(11):1545-51. Epub 2007 Apr 24.

PMID:
17459472
34.

Early detection and rapid isolation of leukemia-reactive donor T cells for adoptive transfer using the IFN-gamma secretion assay.

Jedema I, Meij P, Steeneveld E, Hoogendoorn M, Nijmeijer BA, van de Meent M, van Luxemburg-Heijs SA, Willemze R, Falkenburg JH.

Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):636-43.

35.

Involvement of caspase-8 in chemotherapy-induced apoptosis of patient derived leukemia cell lines independent of the death receptor pathway and downstream from mitochondria.

de Vries JF, Wammes LJ, Jedema I, van Dreunen L, Nijmeijer BA, Heemskerk MH, Willemze R, Falkenburg JH, Barge RM.

Apoptosis. 2007 Jan;12(1):181-93.

PMID:
17136321
36.

Chromosomal aberrations in leukaemia cells may delete tumour target antigens of stem cell-based immunotherapy.

Hambach L, Nijmeijer BA, Drabbels JJ, Falkenburg JH, Goulmy E.

Leukemia. 2006 Jul;20(7):1298-300. Epub 2006 Apr 20. No abstract available.

PMID:
16628185
37.

Human cytotoxic T lymphocytes specific for a single minor histocompatibility antigen HA-1 are effective against human lymphoblastic leukaemia in NOD/scid mice.

Hambach L, Nijmeijer BA, Aghai Z, Schie ML, Wauben MH, Falkenburg JH, Goulmy E.

Leukemia. 2006 Feb;20(2):371-4. No abstract available.

PMID:
16357839
39.

Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.

Jedema I, Barge RM, van der Velden VH, Nijmeijer BA, van Dongen JJ, Willemze R, Falkenburg JH.

Leukemia. 2004 Feb;18(2):316-25.

PMID:
14614514
40.

Recruitment of leukemic cells from G0 phase of the cell cycle by interferons results in conversion of resistance to daunorubicin.

Jedema I, Barge RM, Nijmeijer BA, Willemze R, Falkenburg JH.

Leukemia. 2003 Oct;17(10):2049-51. No abstract available.

PMID:
14513057
42.

15-deoxy-delta12,14-prostaglandin J2-induced apoptosis in amnion-like WISH cells.

Keelan J, Helliwell R, Nijmeijer B, Berry E, Sato T, Marvin K, Mitchell M, Gilmour R.

Prostaglandins Other Lipid Mediat. 2001 Dec;66(4):265-82.

PMID:
11785780
43.

Angiotensin-1-converting enzyme and angiotensinogen gene polymorphisms in Maori and Pacific Island people in New Zealand.

Kyle CV, Abbott W, Young RP, Nijmeijer B, Simmons D, Braatvedt GD.

Intern Med J. 2001 Mar;31(2):116-8. No abstract available.

PMID:
11480474
44.

Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice.

Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL, Kluin-Nelemans HC, Willemze R, Falkenburg JH.

Exp Hematol. 2001 Mar;29(3):322-9.

PMID:
11274760
45.

The mechanism of N-acetylcysteine photoprotection is not related to dipyrimidine photoproducts.

Nijmeijer BA, Steenvoorden DP, Beijersbergen van Henegouwen GM, Roza L, Vink AA.

J Photochem Photobiol B. 1998 Jul 31;44(3):225-30.

PMID:
9800381
46.

The Hermansky-Pudlak syndrome. Evidence for a lowered 5-hydroxytryptamine content in platelets of heterozygotes.

Gerritsen SM, Akkerman JW, Nijmeijer B, Sixma JJ, Witkop CJ, White J.

Scand J Haematol. 1977 Mar;18(3):249-56.

PMID:
847398

Supplemental Content

Loading ...
Support Center